Clinical Trials

View onClinicalTrials.gov
Development Highlights
1. Dual-Target Mechanism:
A single GalNAc-siRNA designed to simultaneously silence PCSK9 and ANGPTL3, addressing complementary pathways in LDL-C and triglyceride-rich lipoprotein metabolism.
2. First-in-Class Development:
MWX205 is the world’s first PCSK9/ANGPTL3 dual-target siRNA to enter clinical development, with a Phase 1 clinical program underway.
3. Potential for Comprehensive Lipid Management:
Designed to address both elevated LDL-C and triglycerides, with the potential to simplify long-term lipid management by integrating two lipid-lowering mechanisms into a single therapeutic.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
